Characteristics of polycystic ovary syndrome throughout life.

adolescence amenorrhea anovulation cardiovascular disease diabetes mellitus health risks hyperandrogenism menopause oligomenorrhea polycystic ovarian morphology polycystic ovary syndrome

Journal

Therapeutic advances in reproductive health
ISSN: 2633-4941
Titre abrégé: Ther Adv Reprod Health
Pays: England
ID NLM: 101765379

Informations de publication

Date de publication:
Historique:
received: 11 02 2020
accepted: 12 02 2020
entrez: 11 6 2020
pubmed: 11 6 2020
medline: 11 6 2020
Statut: epublish

Résumé

Polycystic ovary syndrome is the most common endocrine disorder in women of reproductive age. It is a complex disease in which genetic, endocrine, environmental, and behavioral factors are intertwined, giving rise to a heterogeneous phenotype with reproductive, metabolic, and psychological characteristics. Polycystic ovary syndrome affects women's health and their quality of life across the life course. During different life stages, the polycystic ovary syndrome phenotype can change, which requires a personalized diagnostic approach and treatment. Polycystic ovary syndrome is a major cause of anovulatory infertility; this disorder is also associated with hirsutism and acne. Diagnosing polycystic ovary syndrome during adolescence is challenging because the polycystic ovary syndrome criteria include normal physiological events that occur during puberty. With increasing age, the syndrome evolves from a reproductive disease to a more metabolic disorder. Along with metabolic disturbances, including insulin resistance and abnormalities of energy expenditure, polycystic ovary syndrome is recognized as a major risk factor for the development of type 2 diabetes and cardiovascular disease in later life. Moreover, there is evidence for familial clustering of endocrine and metabolic features of polycystic ovary syndrome. Environmental factors such as diet and obesity appear to contribute to the phenotype. Treatment should be tailored to the specific concerns and needs of the individual patient and involves restoring fertility, treatment of the metabolic complaints, treatment of androgen excess, and providing endometrial protection. The complexity of the disorder, and the impact on quality of life, requires a timely diagnosis, screening for complications, and management strategies for the long-term health issues associated with polycystic ovary syndrome. The syndrome remains underdiagnosed, and women experience significant delays to diagnosis.

Identifiants

pubmed: 32518918
doi: 10.1177/2633494120911038
pii: 10.1177_2633494120911038
pmc: PMC7254582
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

2633494120911038

Informations de copyright

© The Author(s), 2020.

Déclaration de conflit d'intérêts

Conflict of interest statement: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Références

Ann Hum Biol. 1984 Nov-Dec;11(6):495-508
pubmed: 6524865
Endocr Rev. 2015 Oct;36(5):487-525
pubmed: 26426951
J Clin Endocrinol Metab. 2016 Feb;101(2):739-47
pubmed: 26652764
J Clin Endocrinol Metab. 2019 Mar 1;104(3):809-818
pubmed: 30590587
Fertil Steril. 2017 Mar;107(3):788-795.e2
pubmed: 28089571
Trends Endocrinol Metab. 1998 Feb;9(2):58-61
pubmed: 18406242
Hum Reprod Update. 2011 Jul-Aug;17(4):495-500
pubmed: 21335359
Mol Cell Endocrinol. 2013 Jul 5;373(1-2):91-7
pubmed: 23261983
Am J Obstet Gynecol. 2011 Jun;204(6):558.e1-6
pubmed: 21752757
J Clin Endocrinol Metab. 2006 Dec;91(12):4842-8
pubmed: 17003085
Hum Reprod. 2011 Jun;26(6):1462-8
pubmed: 21427116
J Clin Endocrinol Metab. 1982 Feb;54(2):241-6
pubmed: 6798063
J Womens Health (Larchmt). 2015 Apr;24(4):299-307
pubmed: 25654626
Arch Dis Child. 2018 Mar;103(3):235-239
pubmed: 28794095
Hum Reprod. 2010 Jun;25(6):1497-503
pubmed: 20356900
Fertil Steril. 2011 Feb;95(2):702-6.e1-2
pubmed: 20650451
Hum Reprod Update. 2010 Jan-Feb;16(1):51-64
pubmed: 19567450
Eat Weight Disord. 2019 Oct;24(5):787-797
pubmed: 29947018
Fertil Steril. 2018 Oct;110(5):794-809
pubmed: 30316414
J Clin Endocrinol Metab. 2004 Feb;89(2):453-62
pubmed: 14764747
Fertil Steril. 2012 Jan;97(1):13-7
pubmed: 22192136
J Clin Endocrinol Metab. 1999 Jan;84(1):165-9
pubmed: 9920077
J Clin Endocrinol Metab. 2014 Jun;99(6):2120-7
pubmed: 24517154
Cochrane Database Syst Rev. 2019 Mar 28;3:CD007506
pubmed: 30921477
Metabolism. 2019 Mar;92:108-120
pubmed: 30445140
J Clin Endocrinol Metab. 2009 May;94(5):1579-86
pubmed: 19240158
Obstet Gynecol. 2011 Jan;117(1):145-52
pubmed: 21173657
Clin Endocrinol (Oxf). 2018 Feb;88(2):169-184
pubmed: 28930378
Endocr Pract. 2015 Dec;21(12):1415-26
pubmed: 26642102
J Clin Endocrinol Metab. 2011 Dec;96(12):3794-803
pubmed: 21956415
J Clin Endocrinol Metab. 2017 Oct 1;102(10):3848-3857
pubmed: 28938447
Fertil Steril. 2003 May;79(5):1154-60
pubmed: 12738511
Hum Reprod. 2017 May 1;32(5):1075-1091
pubmed: 28333286
Hum Reprod. 2004 Jan;19(1):41-7
pubmed: 14688154
Fertil Steril. 2011 Nov;96(5):1259-65
pubmed: 21963227
Nat Rev Dis Primers. 2016 Aug 11;2:16057
pubmed: 27510637
Hum Reprod. 2004 Feb;19(2):383-92
pubmed: 14747186
Compr Psychiatry. 2011 Sep-Oct;52(5):486-9
pubmed: 21193185
Nat Commun. 2015 Sep 29;6:8464
pubmed: 26416764
Obes Rev. 2019 May;20(5):659-674
pubmed: 30674081
Hum Reprod Update. 2010 Jul-Aug;16(4):347-63
pubmed: 20159883
Fertil Steril. 2011 Mar 1;95(3):1073-9.e1-11
pubmed: 21247558
Int J Impot Res. 2013 Jul-Aug;25(4):127-32
pubmed: 23407282
J Clin Endocrinol Metab. 2008 Jan;93(1):162-8
pubmed: 17925334
Fertil Steril. 2018 Feb;109(2):356-364.e32
pubmed: 29331234
Acta Obstet Gynecol Scand Suppl. 1971;14:Suppl 14:1-36
pubmed: 5290914
Pituitary. 2019 Apr;22(2):170-178
pubmed: 30798438
Reprod Biomed Online. 2018 Dec;37(6):750-760
pubmed: 30420168
Hum Reprod Update. 2006 Nov-Dec;12(6):673-83
pubmed: 16891296
Am J Hypertens. 2015 Jul;28(7):847-51
pubmed: 25542625
Cardiovasc Diabetol. 2018 Mar 8;17(1):37
pubmed: 29519249
J Endocrinol. 1983 May;97(2):213-9
pubmed: 6854190
Lancet Diabetes Endocrinol. 2020 Feb;8(2):134-149
pubmed: 31635966
J Clin Endocrinol Metab. 2008 Feb;93(2):470-6
pubmed: 18056772
Int J Fertil. 1967 Jan-Mar;12(1 Pt 2):77-126
pubmed: 5419031
Horm Res Paediatr. 2015 Apr 1;:
pubmed: 25833060
Clin Endocrinol (Oxf). 2006 Aug;65(2):137-45
pubmed: 16886951
Semin Cutan Med Surg. 2010 Jun;29(2 Suppl 1):2-4
pubmed: 20610306
Diabetes. 2012 Sep;61(9):2369-74
pubmed: 22698921
Fertil Steril. 2017 Aug;108(2):333-340
pubmed: 28778282
Hum Reprod. 2018 Sep 1;33(9):1602-1618
pubmed: 30052961
Med Clin North Am. 2008 Sep;92(5):1163-92, xi
pubmed: 18721657
Iran J Reprod Med. 2014 Aug;12(8):539-46
pubmed: 25408703
Reprod Biol Endocrinol. 2013 Jun 26;11:56
pubmed: 23800002
Semin Reprod Med. 2018 Jan;36(1):5-12
pubmed: 30189445
J Clin Endocrinol Metab. 2005 Aug;90(8):4650-8
pubmed: 15944216
J Clin Endocrinol Metab. 2018 Apr 1;103(4):1622-1630
pubmed: 29408955
Hum Reprod. 2014 Jun;29(6):1327-36
pubmed: 24777850
Obstet Gynecol. 2011 Jan;117(1):6-13
pubmed: 21173640

Auteurs

Yvonne V Louwers (YV)

Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynaecology, Erasmus University Medical Centre, 3000 CA, Rotterdam, The Netherlands.

Joop S E Laven (JSE)

Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynaecology, Erasmus University Medical Centre, Rotterdam, The Netherlands.

Classifications MeSH